Stockwinners Market Radar for August 04, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:26 EDT Cathie Wood's ARK Investment bought 212K shares of Pacific Biosciences today

19:47 EDT Atlas Corp. confirms receipt of "Take Private" proposal - Atlas announced that its board of directors has received a non-binding proposal letter, dated August 4, 2022, from Poseidon Acquisition Corp. , an entity formed by certain affiliates of Fairfax Financial Holdings Limited, certain affiliates of the Washington Family, David Sokol, Chairman of the Board of Atlas, and Ocean Network Express Pte. Ltd., and certain of their respective affiliates, to acquire all of the outstanding common shares of Atlas, other than common shares owned by Fairfax, Washington, Mr. Sokol and certain executive officers of the Company, for $14.45 cash per common share. Fairfax, Washington and Mr. Sokol, together with certain of their respective affiliates, collectively own more than 50% of the Company's outstanding common shares. The proposal letter states that a transaction would be subject to two non-waivable conditions: approval and recommendation by a special committee of independent directors of the Board and approval by the holders of a majority of the outstanding common shares of the Company not owned by the Consortium. The proposal letter indicated the proposal may be modified or withdrawn at any time. The Board intends to establish a special committee consisting of independent directors of the Board to consider the proposal.

19:33 EDT JetBlue announces direct flight from Boston's Logan Airport to London's Gatwick - JetBlue "announced it has officially launched service from Boston's Logan International Airport to London's Gatwick Airport. JetBlue's daily nonstop service is part of the airline's focus city strategy and its long-term transatlantic growth plans. London was the largest nonstop market not currently served by JetBlue from Boston and is among the most requested destinations from the airline's large Boston customer base."

18:56 EDT Pinterest CEO buys $5M in common stock - In a regulatory filing, Pinterest disclosed that its CEO William Ready bought 222K shares of common stock on August 3rd in a total transaction size of $5.0M.

18:02 EDT Parsons awarded $104.2M Missile Defense Agency contract - Parson's was awarded a competitive cost-plus-fixed-fee, level-of-effort contract with a total value of $104.2M. Under this new contract, the contractor will provide support to plan, program, acquire, design, and construct sustainable, environmentally efficient facilities and infrastructure; execute the Missile Defense Agency, or MDA, military construction and sustainment, restoration, and modernization programs; and manage the MDA Real Property Program. The performance period is from August to February 2028. This contract was competitively procured via publication on the SAM.gov website with three proposals received. FY22 research, development, test and evaluation funds in the amount of $1.72M are being obligated on this award. The Missile Defense Agency is the contracting activity.

18:00 EDT General Dynamics awarded $535.02M Navy contract modification - General Dynamics was awarded a $535.02M modification to a previously awarded contract for the procurement of detail design and construction of Expeditionary Sea Base, or ESB 8. Work is expected to be completed by March 2026. FY22 shipbuilding and conversion funds in the amount of $535.02M will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:39 EDT GoPro says seeing 'solid demand,' expects ASPs to go up in 2023

17:29 EDT Custom Truck One Source announces $30M share repurchase program - Custom Truck One Source announced that its Board of Directors authorized a stock repurchase program for up to $30M of the company's common stock.

17:28 EDT Beyond Meat sees reduction in warehouse costs following reduction in inventory - Says has been delayed in getting extended shelf-life versions of non-burger products.

17:24 EDT GoPro sees 2.9M-3.1M cameras sold in 2022, down from prior view of 3.2M units - Sees stronger sales of units in 2H22 vs. 1H22. Sees FY22 gross margin at low end of 40%-43% range. Sees FY22 OpEx $325M-$330M. Comments taken from Q2 earnings conference call.

17:22 EDT Clearfield to replace Celsius Holdings in S&P 600 at open on 8/10 - S&P SmallCap 600 constituent Celsius Holdings (CELH) will replace American Campus Communities (ACC) in the S&P MidCap 400, and Clearfield (CLFD) will replace Celsius Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, August 10. Blackstone (BX) is acquiring American Campus Communities in a transaction expected to be completed soon pending final conditions.

17:19 EDT Health Catalyst announces $40M share repurchase program - Health Catalyst announced that its board of directors approved a share repurchase program with authorization to purchase up to $40M of its Common Stock, effective immediately."This share repurchase program demonstrates our confidence in the future of our business and our commitment to creating long-term, sustainable value for our shareholders, our customers and our team members," said Dan Burton, CEO of Health Catalyst. "We believe the current market does not reflect the long-term value of our shares of common stock and this share repurchase program will allow us to unlock more of the long-term value and opportunity we see ahead."

17:18 EDT Expedia says spending below historical levels - Says fixated on share. Says competition has been highly promotional. Comments taken from Q2 earnings conference call.

17:17 EDT Warner Bros. Discovery sees FY23 adjusted EBITDA of 'at least $12B'

17:15 EDT Volaris reports preliminary July traffic - In July 2022, Volaris' capacity (measured in ASMs) increased 28.8% compared to July 2021, while demand (measured in RPMs) increased 21.9% compared to the same period; the result was a load factor of 84.7% (-4.8 pp YoY). Volaris transported 2.8 million passengers during the month, a 22.2% increase compared to July 2021. Passenger demand (RPMs) in the domestic Mexican and international markets increased 22.8% and 19.6%, respectively, compared to July 2021. Year-to-date, Volaris' demand (measured in RPMs) increased 32.2% YoY, with a load factor expansion of 0.1 pp, to 84.1%.

17:12 EDT 3D Systems announces Michael Turner hired as CFO - 3D Systems announced that Michael Turner will join the company as Executive Vice President and Chief Financial Officer, effective August 29. He will report to President and CEO, Dr. Jeffrey Graves, and will lead the company's global finance organization, including accounting and controllership, financial planning, tax, treasury, and investor relations.Michael brings an exemplary technical background to the CFO role that includes public accounting experience as well as financial leadership roles of increasing responsibility at both public and private companies. Currently, Michael is Chief Financial Officer of Innovative Chemical Products

17:04 EDT Dropbox backs long-term gross margin targets of 80%-82% - Backs forecast of $1B free cash flow by 2024 and 30%-32% operating margin. Reference Link

16:57 EDT Atlassian names Microsoft's Joe Binz as new CFO - Atlassian (TEAM) announced that Joe Binz will join the company as its new Chief Financial Officer and Principal Financial Officer, effective September 6. Since 2014, he has held the role of Corporate Vice President, Finance at Microsoft (MSFT), where he was responsible for leading the company's financial planning and analysis, investor relations, acquisition integration, and procurement functions.

16:51 EDT Block sees Square GPV up 18% year-over-year in July - Block said: We wanted to provide an update on the trends in our business during the month of July. For the third quarter of 2022, we believe three-year compound annual growth rates from 2019 through 2022 will help reflect underlying trends in each ecosystem, given the variability in year-over-year and two-year CAGR comparisons due to COVID-19. For the month of July, Square GPV is expected to be up 18% year over year. On a three-year CAGR basis, GPV growth is expected to be 23% in July, consistent with 23% growth in the second quarter. In July, we expect Cash App gross profit, excluding our BNPL platform, to grow on a year-over-year and three-year CAGR basis, driven by growth in monthly transacting actives, engagement across our ecosystem, and inflows into Cash App."

16:43 EDT Lyft sees ride-share volumes exceeding pre-COVID levels - Says saw increased demand in Q2. Sees ride-share volumes to reach and exceed pre-COVID levels in the medium-term. Says pulled back on discretionary spending in Q2. Comments taken from Q2 earnings conference call.

16:40 EDT SPX to execute tax-free merger of SPX Corp with, into SPX Merger

16:39 EDT SPX Corporation announces plan to reorganize legal structure - SPX announced that it intends to implement a reorganization of its corporate legal structure by executing a tax-free merger of SPX Corporation with and into SPX Merger, LLC, a newly-formed Delaware limited liability company that is a subsidiary of a newly-formed Delaware corporation, SPX Technologies, Inc. As a result of the transaction, SPX Technologies will become the holding company for the SPX group of companies, and will be the publicly traded entity. Immediately after consummation of the transaction, SPX Technologies will have, on a consolidated basis, the same assets, businesses, operations, executive officers, officers and directors as SPX had immediately prior to the consummation of the transaction. As a result of the new structure, the operating assets of SPX will be separated from certain legacy liabilities and associated insurance assets.Upon completion of the new structure, which the company is targeting to occur on or about August 15, 2022, the SPX common stock will continue trading on the NYSE on an uninterrupted basis with no change to the ticker symbol "SPXC." The company anticipates multiple benefits from the transaction including a simpler and more efficient legal structure to accommodate growth through acquisitions, and opportunities for more efficient management of legacy liabilities.

16:36 EDT NGM Bio on track for topline data readout of Phase 2 trial in Q4 - The company said it remains on track for topline data readout of the Phase 2 CATALINA trial of NGM621 in patients with geographic atrophy in the fourth quarter of 2022, to be followed by a planned presentation of results at a medical conference in the same quarter.

16:33 EDT TripAdvisor sees seasonal step down in adjusted EBITDA margin in Q4 vs. Q3 - The company said: "We expect a seasonal step down in consolidated adjusted EBITDA margin in Q4 versus Q3. In addition, in 2H we expect to partly reinvest the Q2 2022 COVID-19 related benefit in TheFork." It also said: "Like many in the travel industry, we have seen that consumers were still spending on travel, despite some of the macro uncertainties, the geopolitical atmosphere, and even lingering COVID-19 flare-ups. However, as we embark on the 2H, it's difficult to predict the probability, or the magnitude, of macro weakness, or of currency movements, and how they might impact the 2H of 2022 and the start of 2023. Despite these factors, we expect modest improvement from Q2 recovery levels across segments, and flattening in the 2H, partly driven by the impact of currency."

16:32 EDT Carlisle raises quarterly dividend 39% to 75c per share - Carlisle Companies announced that its Board of Directors has approved a 39% increase in the Company's regular quarterly dividend from $0.54 to $0.75 per share, or to $3 per share on an annualized basis. The dividend is payable on September 1, 2022, to shareholders of record at the close of business on August 18, 2022. Chris Koch, Chair, President and Chief Executive Officer, said "As part of our legacy of being superior capital allocators, we are very pleased to announce a dividend increase for the 46th consecutive year. This 39% increase is our largest in the past 25 years, and reflects our strong, sustainable financial position, and confidence in continued growth of Carlisle's earnings power. Our commitment to returning capital to shareholders is made possible by the support of Carlisle's dedicated employees, who embrace our culture of continuous improvement and maintain a steadfast commitment to creating value for all stakeholders."

16:31 EDT FuboTV reports Q2 subscribers up 41% y/y - Reports Q2 ad revenue up 32% and ad ARPU down 18% y/y.

16:30 EDT Quaker Houghton sees sequential GM expansion, earnings growth in 2H

16:29 EDT AT&T, Warner Bros. Discovery announces distribution pact for HBO Max - AT&T (T) and Warner Bros. Discovery (WBD) announced an agreement that will allow AT&T to continue to offer internet and mobility customers access to HBO Max's portfolio of original programming and series. "HBO Max is a great product that is popular with our customers, and we like the fact that we're viewed as being the place to come to get it," said Jenifer Robertson, EVP & General Manager - Mass Markets, AT&T Inc. "This adjusted agreement represents an important step in positioning both AT&T and Warner Bros. Discovery for continued success."

16:24 EDT TripAdvisor sees revenue continuing to improve vs. 2019 in Q3 - Comments taken from TripAdvisor's Q2 shareholder letter.

16:23 EDT Zillow, Opendoor announce multi-year partnership - Zillow (Z;ZG) and Opendoor Technologies (OPEN) have announced a multi-year partnership that "combines two category leaders to transform how people start their move." The partnership will allow home sellers on the Zillow platform to seamlessly request an Opendoor offer to sell their home, the companies stated. "Zillow and Opendoor are working together to launch this new product experience with the goal of serving shared customers nationwide in the coming months and years," they added.

16:21 EDT Premier raises quarterly dividend 5% to 21c per Class A share - Premier, Inc. announced that its Board of Directors approved a 5% increase to the company's quarterly cash dividend to $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable on September 15, 2022, to stockholders of record as of the close of business on September 1, 2022.

16:17 EDT Duolingo reports 51% increase in total booking from the prior year quarter - Total bookings were $97.5 million, an increase of 51% from the prior year quarter; Paid Subscribers totaled 3.3 million at quarter end, an increase of 71% from the prior year quarter; Monthly active users (MAUs) grew 31% to 49.5 million from the prior year quarter and Daily active users grew 44% to 13.2 million from the prior year quarter;

16:13 EDT Universal Display CFO Rosenblatt to retire - Universal Display announced that following a brilliant and remarkable 26 years with the Company, Sidney D. Rosenblatt plans to retire as CFO at the end of this year. Rosenblatt will remain on the Company's Board of Directors. Universal Display also announced today that Brian Millard has been appointed Chief Financial Officer, effective September 6, 2022. "It has been a wondrous and tireless two-and-a-half-plus decades of building and shaping Universal Display Corporation from a three-person startup to a successful global leader that continues to be at the forefront of the OLED industry," said Rosenblatt. "I am grateful for my incredible journey at UDC and look forward to working with Brian to ensure a smooth transition. Sherwin (Seligsohn), Steve and I took this Company public in 1996 with one patent pending, a research contract with Princeton University and a vision to revolutionize the display industry. The next 15 years were filled with triumphs, challenges, unwavering determination and an unshakeable belief in the future of OLEDs and the Company. In 2011, we achieved profitability and UDC's earnings have reached new record levels ever since. It has been a distinct honor to help lead this amazing company and to work alongside phenomenal and dedicated people through these many years. I am humbled by and proud of all of UDC's accomplishments and am confident that the future of the Company is exceptionally strong."

16:12 EDT Doma to complete reverse stock split at next annual stockholder meeting - Doma announced its intention to complete a reverse stock split, subject to approval by its board of directors and stockholders at its next annual meeting of stockholders. The proposed stock split is intended to resolve the issue raised in a non-compliance notice Doma received from the New York Stock Exchange (NYSE) on August 1, 2022 regarding its continued listing standard as set forth in Section 802.01C of the NYSE Listed Company Manual, due to the average closing price of the company's common stock being less than $1.00 per share over a consecutive 30 trading-day period. The NYSE notice does not affect Doma's business operations.

16:12 EDT New Relic names David Barter CFO - New Relic announced David Barter as the company's next Chief Financial Officer. In this role, Barter will oversee global finance operations. Barter will assume the CFO role from Mark Sachleben, who, as previously announced, will retire from the company after 14 years of service. "David brings exceptional experience accelerating the business goals of high growth companies like Microsoft and General Electric, and is the right leader to be our next CFO," said New Relic CEO Bill Staples. "His fresh perspective, integrity, decisiveness, and accountability will be invaluable to New Relic as we continue to drive our long-term growth strategy of putting the power of data in the hands of the world's software engineers." Barter brings nearly three decades of high-growth public and private company finance experience to New Relic. Most recently, Barter served as CFO of C3 AI, where he led the company through a successful IPO. Previously, he held the CFO position at Model N and led finance teams at Microsoft, General Electric, and Guidewire Software. Barter is an established business leader with proven success leading the financial strategies of public companies in the technology sector. He holds a Master of Business Administration and Master of Engineering Management from Northwestern University's Kellogg School of Management, and a Bachelor of Business Administration in Finance and Philosophy from University of Notre Dame.

16:06 EDT Cerus backs FY22 product revenue view of $160M-$165M

16:05 EDT Skyworks raises quarterly dividend 11% to 62c per share - Skyworks' board of directors has declared a cash dividend of $0.62 per share of the Company's common stock, representing an 11% increase from the prior quarterly dividend of $0.56 per share. The dividend is payable on Sept. 15, 2022, to stockholders of record at the close of business on Aug. 25, 2022.

14:56 EDT Vinco Ventures halted by Nasdaq for 'additional information requested' - The Nasdaq Stock Market announced that trading was halted today in Vinco Ventures (BBIG) at 01:44:39 P.M. Eastern Time for "additional information requested" from the company at a last sale price of $0.7117. "Trading will remain halted until Vinco Ventures, Inc. has fully satisfied Nasdaq's request for additional information," the exchange stated.

14:06 EDT Aeterna Zentaris trading resumes

13:56 EDT Globis Acquisition Corp trading resumes

13:20 EDT Shake Shack sees FY22 domestic company-operated openings 35-40 - Sees FY22 general and administrative expenses$111M to $113M. This information was taken from a company slides presentation put earlier.

13:03 EDT Siga, Chimerix rallyafter WaPo report of monkeypox emergency declaration

12:45 EDT 3M commences splitoff exchange offer for food safety business - 3M Company (MMM) announced the commencement of an exchange offer to effect the separation of its food safety business, in furtherance of the previously announced Reverse Morris Trust transaction with Neogen Corporation (NEOG) through the merger of Garden SpinCo Corporation, currently a wholly-owned subsidiary of 3M formed to hold the Food Safety Business, with a subsidiary of Neogen. 3M stockholders have the option to exchange some, all or none of their shares of 3M common stock for shares of common stock of SpinCo, subject to proration as described below. Shares of SpinCo common stock will convert automatically into the right to receive shares of Neogen common stock at the closing of the Merger, which is expected to occur promptly after completion of the exchange offer. Tendering 3M stockholders are expected to receive approximately $107.53 of Neogen common stock for every $100.00 of shares of 3M common stock tendered and accepted in the exchange offer. 3M will determine the prices at which shares of 3M common stock and shares of SpinCo common stock will be exchanged by reference to the simple arithmetic average of the daily volume-weighted average prices of shares of 3M common stock on the New York Stock Exchange and shares of Neogen common stock on the Nasdaq Global Select Market on each of the last three full trading days ending on and including the second full trading day prior to the expiration date of the exchange offer. 3M currently expects that approximately 108.3 million shares of SpinCo common stock will be available in the exchange offer, with the final number dependent on the number of outstanding shares of Neogen common stock outstanding immediately prior to the closing of the Merger.

12:37 EDT Eli Lilly ordered to pay $61M for Medicaid fraud, law firm says - A jury has ordered Eli Lilly to pay over $61M in damages eight years after whistleblower Ronald Streck filed a False Claims Act lawsuit alleging that the company underpaid the rebates required of drug manufacturers under the Medicaid Drug Rebate Program. Under the False Claims Act, damages are trebled and the final judgment will be over $183M, law firm Walden Macht & Haran said in a statement.

12:07 EDT Yum! Brands appoints Allyson Park as CCAO - Yum! Brands announced that it has named Allyson Park to the role of Yum! Brands Chief Corporate Affairs Officer, effective August 15, 2022. Park will have oversight of all aspects of the Company's Communications, Public Policy and Government Relations, Corporate Social Responsibility and Environmental, Social and Governance teams. Park will join the Company's Global Leadership Team, and report to Yum! Brands Chief Operating Officer and Chief People Officer Tracy Skeans. Most recently, she worked for Mars, Incorporated serving as Global Vice President, Corporate Affairs, for Mars Wrigley.

12:01 EDT Aris Water Solutions falls -28.0% - Aris Water Solutions is down -28.0%, or -$6.25 to $16.07.

12:01 EDT AMTD Digital falls -38.1% - AMTD Digital is down -38.1%, or -$418.79 to $681.21.

12:00 EDT Altice USA rises 14.6% - Altice USA is up 14.6%, or $1.41 to $11.08.

11:34 EDT Sanofi announces strategic collaboration with Innovent Biologics - Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. "Innovent is a leading biopharmaceutical company with strong clinical development capabilities and a broad commercial footprint in China. Both companies are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III SAR408701 and Phase II SAR444245, combining with sintilimab, the leading checkpoint inhibitor in China. In addition to the collaboration and license agreement, Sanofi will invest EUR 300M in Innovent through subscription of new common shares," Sanofi stated. Subject to mutual agreement of both parties in the future, Sanofi will have the right to acquire additional Innovent new common shares for EUR 300M, at a subscription price that represents 20% premium to Innovent 30-trading-day average share price as the date of the separate agreement that may be entered into by both parties. According to the agreement, Innovent will be responsible for developing and exclusively commercializing tusamitamab in multiple oncology-based indications in China. Sanofi will be entitled to receive up to EUR 80M development milestone payment and royalties on the net sales of the product in China upon approval. Innovent and Sanofi will jointly explore the development of SAR444245 in China in various cancer types, where Innovent will lead the clinical development. Sanofi remains the sole Marketing Authorization holder for both assets and will be fully responsible for SAR245 commercialization. Innovent will be entitled to receive up to EUR 60M development milestone payments and royalties on the net sales of the product in China upon approval.

11:29 EDT American Campus stockholders approve acquisition by Blackstone Funds - American Campus Communities (ACC) announced that, at the concluded special meeting of stockholders held today, its stockholders approved the acquisition of the company by Blackstone Core+ perpetual capital vehicles, primarily comprised of Blackstone Real Estate Income Trust, alongside Blackstone Property Partners L.P. (BX). The transaction is expected to close on or about August 9, subject to the satisfaction or waiver of customary closing conditions. Under the terms of the merger agreement announced on April 19, among other things, each share of the company's common stock issued and outstanding at the effective time of the merger will be automatically cancelled and converted into the right to receive, in accordance with the terms of the merger agreement, an amount in cash equal to $65.47 per share, without interest. Upon closing of the transaction, ACC common stock will no longer be listed on any public market.

11:21 EDT BiomX announces publication of research on BX003 phage candidate - BiomX announced the publication of a scientific paper titled "Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation" in the journal, Cell. The research was conducted across several organizations, including scientists from BiomX and the Weizmann Institute of Science. This research is based on prior work by Prof. Honda et al. from Keio University identifying strains of Klebsiella pneumoniae as potentially disease-causing bacteria in IBD. Looking across four geographically distinct IBD cohorts, researchers identified a clade of Kp strains, featuring a unique antibiotics-resistance and mobilome signature that were strongly associated with IBD disease exacerbation and severity. These strains were then transferred into colitis-prone germ-free and colonized mice to enhance intestinal inflammation. Researchers then demonstrated proof-of-concept assessment of Kp-targeting phages by generating an orally administered, lytic 5-phage combination product specifically designed to target sensitive and resistant IBD-associated Kp clade members through distinct mechanisms. The lytic 5-phage treatment enabled effective Kp suppression in the colitis-prone mice and drove attenuated inflammation and disease severity. Furthermore, the research initially tested Kp-targeting phage in an ex-vivo human gut system and then in a first-in-human, randomized, single-blinded, placebo-controlled clinical trial. Both phage therapies were stable, withstanding shifting biophysical conditions along the human gastrointestinal tract, resulting in accumulation of viable phages in doses expected to enable Kp2 suppression in IBD patients. IBD is a chronic, inflammatory autoimmune disease impacting the gastrointestinal tract, and the bacteria, Klebsiella pneumoniae, has been implicated in the pathogenesis of the disease. BiomX's novel phage candidate, BX003, targets bacterial strains of Kp present in the gut of IBD and primary sclerosing cholangitis patients. As outlined in the research, results from Phase 1a study demonstrated safety and tolerability of the administered phages as well as successful delivery of a high concentration of viable phage to the lower gastrointestinal tract, in alignment with data generated in a human-gut like system.

11:03 EDT Warner Bros. Discovery launches dedicated CNN Originals hub on discovery+ - CNN and Warner Bros. Discovery announced the launch of a dedicated CNN Originals hub on discovery+ domestically. "Beginning August 19, discovery+ subscribers can access a curated selection of library CNN content through a new hub featuring premium programming from the network's prestige brands: CNN Original Series, CNN Films, and HLN Original Series... Select titles from the award-winning CNN Films library will stream exclusively on discovery+. Additional programming from CNN Films and CNN Original Series is available on HBO Max," the company stated.

10:48 EDT Adtran sees Q3 non-GAAP gross margin 35.5%-38.5% - Comments taken from Q2 earnings conference call.

10:32 EDT Embraer affirms all aspects of 2022 financial, deliveries guidance

10:01 EDT Mobile Global Esports Inc trading resumes

10:00 EDT Atento falls -23.3% - Atento is down -23.3%, or -$2.00 to $6.60.

10:00 EDT Fiverr rises 13.0% - Fiverr is up 13.0%, or $4.83 to $41.90.

10:00 EDT Zeta Global rises 15.1% - Zeta Global is up 15.1%, or 94c to $7.16.

09:56 EDT Mobile Global Esports Inc trading halted, volatility trading pause

09:54 EDT Nikola sees SOP for EU-build BEV trucks in 2H23 - Comments taken from Q2 earnings conference call.

09:48 EDT Mace Security enters partnership with NAPA - Mace Security International is announcing a new partnership NAPA. NAPA distributes its products across 6,000 NAPA AUTO PARTS stores, 57 distribution centers, and more than 16,000 NAPA AutoCare and AutoCare Collision Centers throughout the United States.

09:47 EDT AMTD IDEA Group falls -19.8% - AMTD IDEA Group is down -19.8%, or -$1.24 to $5.01.

09:47 EDT Getty Images rises 12.1% - Getty Images is up 12.1%, or $3.56 to $33.00.

09:47 EDT Zeta Global rises 17.3% - Zeta Global is up 17.3%, or $1.07 to $7.29.

09:45 EDT Allied Motion trading resumes

09:41 EDT Coinbase trading resumes

09:39 EDT Cellect Biotechnology Ltd - ADR trading resumes

09:36 EDT Coinbase trading halted, volatility trading pause

09:35 EDT Coinbase jumps 34% to $108.46 after announcing partnership with BlackRock

09:35 EDT Pharming Group NV (ADS) trading resumes

09:34 EDT Kellogg: Q2 was 'exceptional' in North America - Comments taken from Q2 earnings conference call.

09:34 EDT Chewy announces expansion of Insurance and Wellness offering - Chewy announces the expansion of its Insurance and Wellness offering. CarePlus is an exclusive suite of pet-first wellness and insurance plans that are now available in 31 states and will expand nationwide by late 2022, Chewy said in a statement. "The launch of CarePlus is a significant step forward in our mission of making pet healthcare more affordable and accessible," said Mita Malhotra, Vice President of Chewy Health. "Innovating to improve customer experience is the cornerstone of our customer strategy. Our thoughtfully designed and customized selection of wellness and insurance plans will empower pet parents to always say 'yes' to high-quality care that will help their pets live longer, healthier and happier lives."

09:33 EDT KnowBe4 establishes KnowBe4 Ventures - KnowBe4 announced the formation of KnowBe4 Ventures, its venture arm focused on the human layer of cybersecurity. Two existing leading cybersecurity venture funds - Elephant and Ten Eleven Ventures -- are partnering with KnowBe4 on the initiative.

09:32 EDT Processa Pharmaceuticals launches website for uNL awareness - Processa Pharmaceuticals announces that it has launched a new website Necrobiosislipoidicastudy.com. The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica, an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition. Processa Pharmaceuticals is conducting a randomized, double blind, placebo-controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with Necrobiosis Lipoidica.This study is currently recruiting in the United States and is expected to enroll a total of 20 patients.

09:31 EDT Texas Capital Bank appoints Bryan Kucholtz as Head of Private Wealth - Texas Capital Bancshares announced that Bryan Kucholtz has been appointed to serve as Executive Vice President, Head of Private Wealth, effective immediately. Prior to joining Texas Capital Bank, he most recently served as Executive Vice President, Regional Sales Manager, North Texas, at PNC Investments. In his new role, Mr. Kucholtz will be responsible for managing all aspects of Texas Capital Bank's Private Wealth business across the firm's footprint, including Estate and Wealth Planning Strategies, Investment Management, Trust and Estate Administration, Concierge Private Banking, Insurance and Brokerage Services, as well as Online and Mobile Banking. Mr. Kucholtz will report to Mr. Cummings and work with the Private Wealth team to ensure that the company continues to deliver personalized portfolio monitoring, management, and investment solutions to clients nationwide.

09:30 EDT Allied Motion trading halted, volatility trading pause

09:26 EDT ThredUP announces Noelle Sadler as CMO - ThredUP announced that Noelle Sadler has joined the company as its chief marketing officer, or CMO. Sadler will apply her expertise in e-commerce marketing and merchandising to secondhand. She is the company's first dedicated CMO in nearly five years and will report to thredUP president Anthony Marino, who previously oversaw marketing. Sadler joins thredUP from online fashion retailer Lulus, where she most recently served as CMO.

09:25 EDT Terreno Realty buys industrial property in Rancho Dominguez, CA for $32.1M - Terreno Realty acquired an industrial property in Rancho Dominguez, California on August 3 for a purchase price of approximately $32.1M.

09:22 EDT Timber Pharmaceuticals announces pricing of $8M public offering - Timber Pharmaceuticals announced the pricing of a public offering of 66,666,667 shares of its common stock and warrants to purchase up to 66,666,667 shares of its common stock at an offering price to the public of $0.12 per share and associated warrant. The warrants will have an exercise price of $0.12 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about August 8, 2022, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $8.0 million, before deducting the placement agent's fees and other offering expenses payable by Timber. The Company intends to use the net proceeds from this offering for research and development, including clinical trials, working capital and general corporate purposes.

09:20 EDT Tecogen receives repeat order from NYC developer - Tecogen is pleased to announce an additional order from a developer of several residential buildings in New York City. The order for an InVerde cogeneration system for a building being developed in Queens follows three previous orders from the same developer for cogeneration systems for buildings in Brooklyn and the Bronx. A long-term maintenance contract for all of the systems is expected to be signed when construction is complete.

09:14 EDT AMD, ECARX collaborate on digital cockpit in-vehicle computing platform - AMD announced a strategic collaboration with ECARX, a global mobility tech company. The companies will work together on an in-vehicle computing platform for next-generation electric vehicles, EVs, expected to be in mass production for global rollout in late 2023. The ECARX digital cockpit will be the first in-vehicle platform to be offered with AMD Ryzen Embedded V2000 processors and AMD Radeon RX 6000 Series GPUs along with ECARX hardware and software. Combining the experience in automotive digital cockpit design of ECARX with AMD advanced computing power and stunning visual graphic rendering capabilities, the companies aim to deliver an innovative in-car experience. The digital cockpit will launch with advanced features including driver information mode, heads-up display, rear seat entertainment, multiple-displays, multi-zone voice recognition, high-end gaming and a full 3D user experience.

09:12 EDT Embark completes demonstration of emergency vehicle interaction capability - Embark Trucks announced the completion of a public demonstration of its emergency vehicle interaction capability. Working closely with the Texas Department of Public Safety and the Travis County Sheriff's Office, Embark developed the capability for Embark-powered trucks to identify and stop for law enforcement vehicles in situations such as traffic stops, and built communication protocols and standard operating procedures between autonomous trucks and law enforcement officers. On Embark's technical capabilities roadmap, which details the 16 capabilities required to commercially deploy autonomous trucks in the US Sunbelt, the emergency vehicle interaction capability represents the next milestone achieved by the company. With the completion of this successful public demonstration, Embark has now achieved 12 technical milestones on its roadmap, marking another major step towards commercial deployment of its technology. "The ability to engage safely in emergency vehicle interactions is necessary to operate an autonomous vehicle on public roads," said Emily Warren, Head of Public Policy at Embark Trucks. "Law enforcement always needs to be able to stop a commercial vehicle - autonomous or not - to ensure compliance with the law. This capability was designed to work seamlessly within existing law enforcement workflows, without requiring new training or technology investment by first responders."

09:11 EDT Burning Rock Biotech expects to report moderate growth in Q2 revenues y/y - While the Company has not completed preparation of its financial statements for the second quarter of 2022, it expects to report a moderate growth in revenues year-over-year, driven by new product launches and continued growth of its pharma service revenues, offsetting the negative impact of COVID-19 related lockdowns which severely impacted its business volumes in the affected regions.

09:11 EDT Integra Resources closes oversubscribed overnight marketed offering - Integra Resources announced that it has closed its previously announced overnight marketed public offering. Pursuant to the Offering, Integra issued 16,666,667 common shares of the Company, including 1,515,152 Shares issued in connection with the exercise of the over-allotment option granted to the Underwriters in connection with the Offering, at a price of US$0.66 per Share for gross proceeds of US$11 million. In connection with its convertible loan facility of up to US$20 million from Beedie Investments, the Company will draw an initial advance of US$10 million, pursuant to the terms of the credit agreement between Integra and Beedie Capital dated July 28, 2022. Integra will use the net proceeds from the Initial Advance along with the net proceeds from the Offering to advance the development of the DeLamar Project towards the filing of the Plan of Operations, the completion of ~15,000 meters of shallow, oxide definition drilling, aimed at resource expansion for the proposed heap leach operation, and for working capital and general corporate expenses.

09:09 EDT BASF to produce more specialty pyrrolidones in North America - BASF has announced it will produce more N-(2-Hydroxyethyl)-2-Pyrrolidone, HEP, and N-Octyl-2-Pyrrolidone, NOP, at its Geismar, Louisiana, Verbund site. The production is anticipated to be on-stream in the second half of 2022 and will ensure a global supply of HEP and NOP. "Our customers want to continue to grow in the ink, automotive and agricultural markets and will need increasing quantities for the foreseeable future," said Erika Peterman, Senior Vice President, Chemical Intermediates, North America. "We can accompany these growth plans thanks to our double-digit-million-dollar investment by BASF in Geismar."

09:09 EDT Nikola provides operational outlook - The company said, "Nikola Tre FCEV Program Update: In the second quarter, we began Tre FCEV alpha pilot testing with TTSI in Southern California. As of today, the trucks have accumulated over 3,800 miles. We expect to begin FCEV pilot testing with Walmart in Southern California on August 22. During the second quarter, we began building the first Tre FCEV betas. The first batch of betas are scheduled to be complete by the end of August. We expect to build two additional batches of Tre FCEV betas by the end of the fourth quarter. Beta trucks incorporate learnings from the alpha trials and will be used for engineering and product development. Coolidge, Arizona Manufacturing Facility Update: We are ramping up production capacity in Coolidge, Arizona. We expect to increase our throughput to five units per shift by November of this year. Phase 2 expansion is underway and on track to be completed by Q1 2023. H2 Dispensing Station Updates: On August 3, we announced we had made significant progress in partnership with TravelCenters of America on the first hydrogen dispensing station in Ontario, California. We have executed the definitive agreement, agreed on the station design, and have ordered key equipment. We also executed a land lease in Colton, California to build a greenfield hydrogen dispensing station, and entered into an agreement to lease a parcel servicing the Port of Long Beach to build a greenfield hydrogen dispensing station. We anticipate the stations will be complete by Q4 2023."

09:08 EDT Hagerty appoints Russell Page as Chief Data and Information Officer - Hagerty has expanded its senior leadership team with the hiring of Russell Page as its Chief Data and Information Officer. Prior to Hagerty, Page was a member of the General Motors Financial leadership team, serving as the Head of Strategy & Growth for OnStar Insurance. Before GM, Page served as CEO & President of DaRK Capital, a privately held technology holding company, and its worldwide operating subsidiaries.

09:08 EDT Poshmark offers new styles, marketing for back to school season - Poshmark announces new marketing for back to school season. "Back to school represents a fresh start and an opportunity for families, students, and educators to prepare for the school year ahead. Now more than ever, consumers are weighing the balance of stylish back to school looks that make them feel confident with a desire to make their budgets stretch further to get the best value for their money," said Manish Chandra, Founder and CEO of Poshmark. "Poshmark sellers are heeding the call, stocking their closets with millions of must-have back-to-school items that are priced for today's shoppers. Poshmark will continue to be a key destination for the price-conscious yet trend-driven customer, in search of the popular brands and digital conveniences that make it simple and economical to stock up this back to school season."

09:07 EDT Nikola says 'on track' to deliver 300 to 500 production Tre BEV trucks in 2022 - The company said, "We remain on track to achieve the following milestones in 2022: Deliver 300 to 500 production Tre BEV trucks; Successful FCEV alpha pilot testing with Anheuser-Busch and TTSI; Build, validate and test Tre FCEV beta trucks; Announce location, break ground, and commence construction of the first hydrogen production hub in Arizona; Announce two or more dispensing station partners in California."

09:06 EDT Astria Therapeutics initiates STAR-0215 trial - Astria Therapeutics announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for hereditary angioedema, with dosing once every three months or longer. Astria anticipates preliminary results from the Phase 1a trial by year-end. The Phase 1a trial is intended to establish clinical proof of concept for the differentiated profile anticipated for STAR-0215.

09:06 EDT Zip Co. partners with Cover Genius - Cover Genius has announced a partnership with Zip. The partnership expands Zip's BNPL offering by not only protecting purchases in the moment, but also allowing customers to add protection to their recent purchases.

09:05 EDT Panbela Therapeutics expands Aspire trial to Australia - Panbela Therapeutics, announced it has received approval from the Australian Human Research Ethics Committee, HREC, to expand the company's global clinical trial to Australia, to study SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial. The ASPIRE trial is designed as a randomized double-blind placebo-controlled trial, with a primary endpoint of overall survival. Australia marks the second country activated, with approximately 90 additional sites expected to be activated across 10 countries by early 2023. Panbela has commenced screening for eligible patients, with enrollment to the interim analysis expected to complete in early 2024.

09:04 EDT Barletta Pontoon Boats president Bill Fenech to retire - Winnebago Industries announced the planned retirement of Bill Fenech, President, Barletta Pontoon Boats, effective August 26, 2022. Bill Fenech founded Barletta in 2017 with a focus on innovative products, superior quality and a relentless passion for customer satisfaction and quickly built the company into a significant presence in the popular pontoon boat market segment. Barletta was acquired by Winnebago Industries in August 2021, joining the family of premium RV and marine brands including Winnebago, Grand Design RV, Chris-Craft, and Newmar. Under Fenech's leadership and with the strong contributions of the extended team and dealer partners, Barletta Pontoon Boats has continued to grow market share and aspires to be a top three pontoon brand in the U.S. in the future. To enable further product line growth, Barletta recently announced a major capacity expansion project in Bristol, Indiana that will come online in mid-2023.Fenech will be succeeded by Jeff Haradine, who is being promoted to President, Barletta Pontoon Boats, from his current role as Vice President of Sales. Haradine will report to Chris West, Senior Vice President, Enterprise Operations and Barletta, who has driven successful results as the lead integration manager for Barletta's first year under Winnebago Industries ownership. All other Barletta senior leadership team members will remain in their current roles.

09:04 EDT Pulse Biosciences gets FDA 510k clearance of expanded energy settings for CellFX - Pulse Biosciences technology, announced receipt of U.S. Food and Drug Administration clearance of expanded energy settings for use with the family of CellFX System treatments tips in dermatology. "Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatment of benign lesions and to advancing the CellFX System and its capabilities. Clinicians in the U.S. are now able to access broader treatment settings to provide more customized energy delivery specific to individual lesions," said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. "We are pleased with how quickly the FDA cleared these new energy settings based on the data we provided, requiring 53 of the allotted 90-day review period, to determine that the expanded settings are safe and effective for use with the CellFX System. We appreciate the ongoing collaboration with FDA as we continue to expand the clinical applications for the CellFX System."

09:03 EDT Aware to exhibit cybersecurity authentication solutions at Febraban conference - Aware will be demonstrating the many advantages of its mobile passwordless authentication solutions at this year's Febraban Tech conference. Over three days from August 9-11 in Sao Paolo, Brazil, Aware representatives will provide members of the Latin American financial sector with a close look at the many benefits of its fraud-resistant, mobile biometric authentication solutions already proven in the region.

09:01 EDT First Republic names Susie Cranston COO - First Republic announced that Susie Cranston, senior executive VP of First Republic Private Wealth Management, has been named executive VP and COO of First Republic Bank effective September 1. Cranston joined First Republic in 2013 as a member of its Private Wealth Management executive team. Prior to joining First Republic, Cranston spent 12 years at McKinsey & Company where she consulted on strategy, risk management and transformational change for financial services companies.

08:58 EDT MamaMancini's secures convenience store market test for branded meatballs - MamaMancini's announced that it has secured a market test with H.T. Hackney Company, one of the largest wholesale distributors in the United States, for branded MamaMancini's The Original Meatballs in a Cup and four branded Meals for One products in 47 select locations. The market test will include Meatballs in a Cup as well as four ready to heat Meals for One at 47 "Twice Daily" convenience stores in Tennessee, which focuses on fresh quality food and beverage products. The new test placements are expected to begin shipping in September 2022. "Distribution with Hackney's family of retail food service partners is a highly promising milestone in MamaMancini's growing food service vertical," said Carl Wolf, Chief Executive Officer of MamaMancini's. "With over 20,000 locations, a successful test could position us for placement in thousands of Hackney's customer locations throughout the Eastern United States. "We hope this order represents our initial foothold into the estimated 300,000 convenience store, small grocer retailer, delicatessen, sandwich shop and comparable retail outlet market. The market size in food service is significant, with the aforementioned figure not including opportunities in other aspects of food service such as colleges and universities, corporate dining, travel hubs, stadiums, large group meetings and fast food. We believe we can expand our food service products, such as our branded Meatballs in a Cup and Meals for One into traditional supermarket chains and club stores as well, with grab-n-go food offerings increasing in popularity."

08:57 EDT Milestone Scientific enters distribution agreement with Clinical Technology - Milestone Scientific announced that it has re-engaged Clinical Technology, a specialty distributor of medical products in the mid-west and east coast regions of the United States, as a domestic distributor for the CompuFlo Epidural System.

08:56 EDT Scynexis presents data from Phase 3 CANDLE study of oral ibrexafungerp - SCYNEXIS announced the presentation of positive outcomes from its global Phase 3 CANDLE study investigating the safety and efficacy of oral ibrexafungerp for prevention of recurrent vulvovaginal candidiasis, also known as vaginal yeast infection. The results were presented during the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting being held in Boston August 4-6, 2022. The Phase 3 CANDLE study evaluated the efficacy and safety of oral ibrexafungerp compared to placebo in 260 female patients with RVVC, defined as three or more episodes of VVC in the previous 12 months. The primary endpoint was efficacy as measured by the percentage of subjects with clinical success at test-of-cure. The study met its primary endpoint, with 65.4% of patients who received monthly single-day ibrexafungerp treatment achieving clinical success with no recurrence at all, either culture-proven, presumed or suspected, through Week 24, compared to 53.1% of placebo-treated patients. In addition, ibrexafungerp demonstrated superiority over placebo in preventing mycologically proven recurrence of RVVC through Week 24, a key secondary endpoint. No mycologically proven recurrence was detected in 70.8% of patients receiving ibrexafungerp, compared to 58.5% of placebo-treated patients. The advantage of ibrexafungerp over placebo was sustained over the three-month follow-up period and remained statistically significant in both primary and secondary endpoints. In addition, the study evaluated a sub-group of 24 patients who failed to respond to the initial three doses of fluconazole 150 mg on Days 1, 3, and 7. Results show that 71% of patients in the ITT population achieved a significant reduction or elimination of signs and symptoms following ibrexafungerp treatment. In the study, ibrexafungerp was generally safe and well-tolerated. There were no serious drug-related adverse events, and no patients treated with ibrexafungerp discontinued therapy due to adverse events. "These important results highlight ibrexafungerp as a potential oral antifungal therapy that may transform how yeast infections are treated and provide an effective alternative for women with challenging and recurring yeast infections," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "Taken together, these outcomes paint a fuller picture of the potential broad utility of ibrexafungerp, as well as support an additional indication for BREXAFEMME. If approved for prevention of RVVC, ibrexafungerp would have the broadest label in the U.S. for treatment of VVC and prevention of recurrent yeast infection, providing an important treatment option to address this significant unmet need."

08:55 EDT Genasys partns with Boston Red Sox for GEM software - Genasys announced that the Boston Red Sox will use Genasys Emergency Management software to deliver safety alerts and notifications during games, concerts and other events at Fenway Park.

08:55 EDT Surgalign names Amoruso General Counsel, Corporate Secretary - Surgalign announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022. Amoruso brings to Surgalign approximately 25 years of experience serving public companies in various legal, financial and executive roles.

08:53 EDT Gilead to acquire MiroBio for approximately $405M in cash - Gilead Sciences and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405M in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator and has entered Phase 1 clinical trials, with the first patient dosed earlier this week. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response. MiroBio's I-ReSToRE platform has the potential to be used to develop best-in-class agonist antibodies targeting immune inhibitory receptors, a novel approach to the treatment of inflammatory diseases. The I-ReSToRE platform supports identification and development of therapeutics that utilize inhibitory signaling networks with the goal of restoring immune homeostasis for patients. Gilead anticipates advancing additional agonists derived from MiroBio's I-ReSToRE platform, including a PD-1 agonist, MB151, and other undisclosed early-stage programs, over the next several years. Under the terms of the agreement, Gilead will acquire all of the outstanding share capital of MiroBio for a total of $405M in cash consideration, subject to customary adjustments, which is payable at closing. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures. We expect the transaction with MiroBio to reduce Gilead's GAAP and non-GAAP 2022 EPS by approximately 30- 35c. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

08:53 EDT Sabre's GDS marketplace selected by Cain Travel agency - Sabre signed a new distribution agreement with Cain Travel, a US-based travel agency. This new agreement aims to enable Cain Travel to complement services to their customers worldwide, drive efficiencies and support their economic growth by leveraging their proprietary technologies along with Sabre's travel marketplace, GDS. Cain Travel will have access to Sabre's marketplace of more than 400 airlines, 750,000 hotel properties, and hundreds of tour operators, rail, car rental and cruise providers, to sell customized travel packages from suppliers around the world. Additionally, the travel agency will use their proprietary technologies - powered by Sabre API's - along with the reach represented by the Sabre GDS to differentiate its services among their competitors.

08:52 EDT Nano Dimension announces Baker to join company as President - Nano Dimension announced that Dale Baker will join the Company as President of Nano Dimension - Americas, where he will head the expansion of Nano Dimension's U.S. operations as well as lead worldwide sales activity and execute on the Company's current organic and mergers and acquisitions growth strategy. Baker will report to Zivi Nedivi, Global President of Nano Dimension. Baker is replacing Sean Patterson, who is leaving to take a position as a COO of a printed circuit board manufacturer. Prior to joining Nano Dimension, Baker worked at General Electric & Trading and in GE's Electrical Distribution and Control business

08:50 EDT Marpai to acquire Maestro Health - Marpai has signed a definitive agreement to acquire Maestro Health, a TPA servicing over 80 self-insured employers, based in Chicago, Illinois. At the closing the combined company will serve over 40,000 employee lives with expected combined proforma annual revenues of approximately $40M in 2022. Significant cash of over $20M on the combined balance sheet is expected at closing, which is expected to finance the integration of the two companies. The coint company expects to target positive EBITDA within 18 months. The purchase price of $22.1M is due in April 2024, but, subject to the company meeting its obligations under the agreement, may be financed over four years by the seller. The acquisition is expected to more than double Marpai's revenues - exclusive of third parties' share of revenues -, number of customers and number of members it serves. The transaction is expected to close within 60 days. The purchase price of $22.1M will be payable in cash on April 1, 2024. However, subject to the company meeting its obligations under the agreement, this payment may be financed over four years by the seller with minimum annual cash payments, reflecting a 10% per annum cost of capital, of $5M, $6M, $8M and $9M. The cash on the combined company's balance sheet, as well as synergies from the transaction, are expected to drive the joint company's plan of integration, which is expected to include a target of reaching positive EBITDA within 18 months.

08:48 EDT Paramount says 'clearly navigating some near term headwinds' - Says increasing penetration in the streaming market, taking market share. Says "more captivating content on the way." Says the company "continues to shine at the box office." Comments taken from Q2 earnings conference call.

08:47 EDT Crinetics to present analyses of CRN04894 preclinical, Phase 1 results - Crinetics Pharmaceuticals announced that Peter Trainer, M.D., vice president of clinical endocrinology, will review additional analyses from the preclinical and Phase 1 clinical studies of CRN04894 in an oral presentation at the 10th International Congress of Neuroendocrinology, ICN, being held August 7-10, 2022. CRN04894 is an investigational, oral, small molecule adrenocorticotropic hormone antagonist that is being developed by Crinetics for the treatment of Cushing's disease, congenital adrenal hyperplasia and other conditions of excess ACTH. Data from the first-in-human Phase 1 study demonstrated pharmacologic proof-of-concept for CRN04894, as treatment led to reductions in both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations. Additional details on the upcoming presentation are shown below.

08:46 EDT Arcutis Biotherapeutics completes enrollment in INTEGUMENT-1 Phase 3 trial - Arcutis Biotherapeutics announced the enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis. Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor. The Company is continuing enrollment in an identically designed pivotal Phase 3 trial, INTEGUMENT-2, with topline data from both trials expected by end of 2022. If successful, the Company believes that the trials will provide a sufficient basis to submit a supplemental New Drug Application for roflumilast cream 0.15% for the treatment of mild to moderate AD in individuals age six years and older in 2023. "Atopic dermatitis is a chronic condition that typically begins in childhood. The red, itchy rash most frequently occurs on sensitive areas such as the face, and on arms and legs," said Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer at Arcutis. "We are pleased to have completed enrollment in the first of two phase 3 pivotal trials with roflumilast cream 0.15% in individuals with atopic dermatitis age six and older, moving Arcutis one step closer to potentially providing an important new treatment option for the millions of children and adults suffering from this disease. We believe roflumilast cream, if approved, has the potential to be an effective and well-tolerated once-daily non-steroidal therapy for individuals with atopic dermatitis."

08:45 EDT PDS Biotechnology independent DMC recommends VERSATILE-002 trial continuation - PDS Biotechnology announced that its independent Data Monitoring Committee, DMC, met for its scheduled review of PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA for the potential treatment of recurrent or metastatic HPV16-positive head and neck cancer. Data from the 43 patients included both Stage 1 and Stage 2 checkpoint inhibitor naive subjects and Stage 1 CPI refractory subjects in the safety analysis. Assessment of clinical efficacy was not a focus of the DMC meeting review. Based on their review of patients with available safety data, PDS0101 in combination with KEYTRUDA continues to appear safe and well tolerated. Specifically, there were no drug discontinuations related to toxicity as of the DMC review. In addition, there were no Grade 3 or greater treatment-related adverse events attributed to the combination. The DMC recommended continuing the trial with no modifications. "The safety profile of PDS0101 in combination with KEYTRUDA was consistent with previously reported studies of KEYTRUDA alone." mentioned Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. "The safety data in patients with recurrent or metastatic HPV16-positive head and neck cancer continues to appear to be well tolerated. We look forward to evaluating this further in the VERSATILE-002 trial."

08:44 EDT DTE Energy remarkets DTE Energy Company 2019 senior notes - DTE Energy announced it has successfully remarketed the DTE Energy Company 2019 Series F 4.220% Senior Notes due 2024. The optional remarketing was completed pursuant to the terms of the governing documents for the notes that were originally issued as part of Corporate Units of DTE Energy on Nov. 1, 2019. In connection with the remarketing, DTE Energy elected to move up the maturity date of the notes from Nov. 1, 2025 to Nov. 1, 2024. The remarketing is expected to close on Aug. 8, 2022, subject to customary closing conditions. On and after closing, the notes will bear interest at 4.220% per year. DTE Energy will not directly receive any proceeds from the remarketing of the notes. The proceeds will be used to purchase a portfolio of treasury securities maturing on or prior to Nov. 1, 2022, which is the stock purchase contract settlement date for the Corporate Units. It is expected that on Nov. 1, 2022, a portion of the proceeds of the portfolio of treasury securities required to be purchased with the proceeds of the remarketing will be used to settle the stock purchase contracts issued as part of the Corporate Units. The remaining portion of the proceeds of the portfolio of treasury securities will be distributed to the holders of the Corporate Units.

08:42 EDT Sunshine Biopharma files Q2 report with SEC - Sunshine Biopharma announced that it has filed its 2022 second quarter report with the Securities and Exchange Commission. The Report shows that the Company had Cash & Cash Equivalents of $41,727,775 as of June 30, 2022, compared to $2,045,167 as of December 31, 2021. The following are some of the highlights of the Company's 2022 report for the six months ended June 30, 2022: In February, the Company completed a registered securities offering of its Common Stock together with Tradeable Warrants for gross proceeds of approximately $8 million and began trading on the Nasdaq Stock Exchange under the ticker "SBFM" for the Common Stock and "SBFMW" for the Tradeable Warrants. On March 14, 2022, the Company received gross proceeds of an additional $8 million from a private placement of Common Stock and Non-Tradeable Warrants with certain institutional and accredited investors. On February 18, 2022, the Company entered into a research agreement with the University of Arizona for the purposes of advancing the development of novel Coronavirus PLpro inhibitors owned by University of Arizona and University of Illinois Chicago. Under the research agreement, the University of Arizona granted the Company a first option to negotiate for a commercial, royalty-bearing license for all intellectual property pertaining to the research project. During the first six months of 2022, the Company continued to build sales momentum for its Essential 9 science-based supplement, with sales increasing to $272,952 compared to $92,032 in the first half of 2021. The Company had a net loss of $1,775,106 in the first half of 2022, compared to a net loss of $9,064,180 in the first half of 2021. Sunshine Biopharma's CFO, Camille Sebaaly, stated, "We are very pleased with the progress of our Company as a whole. We believe the uplisting to NASDAQ was a major step towards building a world-class pharmaceutical company. The strengthened balance sheet is crucial for our current drug development activities and near-term expansion plans."

08:41 EDT Largo Inc. signs joint venture MOU for commercial deployment of VRFB batteries - Largo's clean energy business, Largo Clean Energy or LCE, has signed a non-binding memorandum of understanding with Ansaldo Green Tech or AGT, to establish a collaboration between the parties for the purpose of the commercial deployment of the company's VCHARGE Vanadium Redox Flow Battery - VRFB - composed of the VRFB stack, the vanadium electrolyte, and the Balance of System, in the European, African, and Middle East markets through the formation of a joint venture between AGT and LCE in Italy. The parties have agreed not to engage in discussion with third parties for the purpose of the development or commercialization of flow battery technologies in the Agreed Markets for a period of 150 days to allow for the negotiation of a definitive agreement. The parties believe that, if successful, the potential JV could address identified needs in the European Energy sector. AGT is a subsidiary of Ansaldo Energia, headquartered in Genoa, Italy, with over 3,500 employees globally.

08:40 EDT Canacol Energy says gas sales averaged 197 MMscfpd in July - Canacol Energy provides the following information concerning its July 2022 natural gas sales and the test results of the Cornamusa 1 exploration well, along with near term drilling plans. Gas sales averaged 197 MMscfpd: Realized contractual natural gas sales were 197 million standard cubic feet per day for July 2022. Cornamusa 1 exploration well tests 12.4 MMscfpd: As announced in June 2022, the Corporation completed the drilling of the Cornamusa 1 exploration well located on the VIM-21 Block operated by Canacol Energy Colombia S.A.S. with 100% working interest. The well encountered multiple gas filled sandstones between 6,010 and 7,514 feet true vertical depth within the primary Cienaga de Oro sandstone reservoir target with average porosity of 21 percent. Following completion, the well was tied into the production facilities and tested. Following an initial clean up period, the well was flow tested for 29 hours at an average rate of 6.7 MMscfd. The final test rate was 12.4 MMscfd with a THP of 2244 psia and a choke of 27/64 in. The well was shut in for a build up period of 5 days, after which the well will be put on permanent production. Forward Drilling Program - Claxon 1 exploration well and Canaflecha 2 development well. The Corporation is currently drilling the Claxon 1 exploration well located on its 100% working interest VIM 5 E&P contract. Claxon 1 is located approximately 2 kilometers to the south of the recently announced Alboka 1 discovery which tested 33 MMscfpd from the CDO sandstone reservoir. Claxon 1 will target the same CDO sandstone reservoirs present at Alboka, and the Corporation anticipates that the well will take approximately 4 weeks to drill, complete, and test. The other rig is being mobilized to drill the Canaflecha 2 development well located on the 100% working interest Esperanza E&E contract. The well is anticipated to spud in early August 2022 and is targeting gas within the Cienaga del Oro in the Canaflecha field discovered in 2008. The Corporation anticipates that the well will take approximately 4 weeks to drill, complete, and test. Normal course issuer bid: During July 2022, the Corporation repurchased 86,632 shares at an average price of CAD $2.25 per share. Thus far in 2022 the Corporation has repurchased a total of 5,394,332 shares for cancellation.

08:38 EDT Oxford Lane estimates NAV per share $5.36-$5.46 as of July 31 - Management's unaudited estimate of the range of the NAV per share of our common stock as of July 31, 2022 is between $5.36 and $5.46. This estimate is not a comprehensive statement of our financial condition or results for the month ended July 31, 2022. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending September 30, 2022 may differ materially from this estimate, which is given only as of July 31, 2022.

08:36 EDT Entourage Health enters exclusive licensing agreement with Irwin Naturals - Entourage Health entered into an exclusive licensing, manufacturing and distribution agreement with Irwin Naturals. The new line of CBD and THC products to be produced under the Agreement, curated by Entourage alongside Irwin's wholly owned subsidiary Irwin Naturals Cannabis, are expected to launch first on Entourage's Starseed Medicinal channel in Q4, 2022, with eventual expansion into retail markets across Canada. Under the terms of the Agreement, Entourage will manufacture the newly formulated suite of Irwin-branded line of softgels in five different varieties: CBD, THC and three additional formulations that include both THC and another cannabinoid. In light of recent recommendations issued by Health Canada's Science Advisory Committee on Health Products Containing Cannabis, the Irwin-branded CBD products could eventually launch over-the-counter in pharmacies across Canada.

08:28 EDT Fangdd Network provides clarification on dismissal of KPMG - Fangdd Network Group announced on August 1, 2022 the dismissal of KPMG Huazhen and the engagement of Audit Alliance as the Company's independent registered public accounting firm to audit and report on the consolidated financial statements of the Company for the year ending December 31, 2022. Following the Initial Announcement, the Company would like to clarify the following: KPMG has advised the Company that July 25, 2022 was the date on which its client-auditor relationship with FangDD ended, based on the Company's communications with KPMG. The audit reports of KPMG on the consolidated financial statements of the Company as of and for the years ended December 31, 2021 and 2020 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, except that KPMG's report on the consolidated financial statements of the Company as of and for the year ended December 31, 2021, contained a separate paragraph stating that "The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2(b) to the consolidated financial statements, the Company has suffered recurring losses from operations and a significant decline in revenue during the year ended December 31, 2021, that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2(b). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

08:27 EDT Marimed, Emack & Bolio's launch new line-up of cannabis infused ice cream - MariMed announced the availability of a new cannabis-infused ice cream. MariMed collaborated with the Boston ice cream brand Emack & Bolio's to develop and market new and innovative vegan and dairy ice cream in outrageous flavors. The ice cream is an extension of MariMed's Betty's Eddies infused fruit chews brand and shares the brand's commitment to being hand-crafted and using all-natural ingredients. MariMed Chief Operating Officer Tim Shaw said, "We pushed ourselves to make our infused cannabis ice cream as delicious as the best-tasting, non-infused products found in local specialty ice cream stores. With thanks to the Emack & Bolio's ice cream magicians and our own rock star team, this new ice cream exceeds that high quality benchmark. It's out-of-this-world delicious."

08:25 EDT Ayr Wellness expands cannabis brand LIT to Massachusetts - Ayr Wellness announced that it has expanded its extensive branded-product portfolio with the award-winning flower brand, LIT. LIT originally launched in Nevada, produced by six-time Jack Herer Cup winning cultivators Tahoe Hydroponics Company, and is now available for wholesale and retail purchase in Massachusetts. Ayr will launch LIT in additional states in the coming weeks and months. "LIT flower is a testament to our commitment to taking the best ingredients - facilities, people, genetics - and cultivating excellent cannabis at scale throughout our organization," said Jonathan Sandelman, Founder and CEO of Ayr Wellness. "Our organization has more cultivation talent than ever, including the Tahoe Hydro team that joined forces with Ayr in February of this year, which has helped lift quality across our entire footprint, as well as introduce new offerings like LIT to delight our customers."

08:24 EDT Emerita Resources reports latest drill results from IBW - Emerita Resources announces additional assay results from the 2022 exploration drilling at its Iberian Belt West, IBW, project. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. All deposits are open for expansion along strike and at depth. The drill program to date has been focused on the Romanera and La Infanta deposits. Drilling continues at both sites with one drill continuing at La Infanta and the remaining rigs at Romanera. At present, drilling is hampered by the high temperatures being experienced in southern Spain. Due to the high fire index rating and to protect the health and welfare of the drillers with daytime temperatures in the plus forty-degree Celsius range, no drilling is permitted between 2:00-8:00 PM. Drilling continues at night and earlier in the day before temperatures get too high.

08:23 EDT Freshii launches Freshii Classics - Freshii, launches Freshii Classics with two new bowls and two new salads in its quick service restaurants - made with the fresh and healthy ingredients common to Freshii's menu. With flavors like Chipotle Cheddar and Sesame Crunch, Freshii is helping customers Get Back to What's Good.

08:22 EDT Gilat Satellite expands contract with IPT - Gilat Satellite Networks announced that Internet para Todos, IPT, in Peru is expanding its contract with Gilat, for 4G cellular backhaul services over the Internet. Gilat provides 4G cellular backhaul services over the internet that are being deployed at more than 100 new sites to provide coverage to rural zones through Gilat's access network. The new multi-year contract addresses 4G connectivity to smaller villages and is expected to further grow over time. "It's an honor to expand this important, continuing work with IPT, helping them to overcome technical and economic barriers to bridge the digital divide and increase connectivity in rural areas," said Arieh Rohrstock, Corporate SVP and General Manager Gilat Peru.

08:20 EDT Entrada Therapeutics enters collaboration with DMCRN - Entrada Therapeutics announced a new collaboration with the Myotonic Dystrophy Clinical Research Network supporting END-DM1. END-DM1 is a natural history study to advance the understanding of disease progression in patients with myotonic dystrophy type 1. This is a non-interventional study designed and conducted by the DMCRN, a network of medical centers with expertise in DM1 clinical care and research that is collecting data to support future clinical trials of potential therapies for DM1. Entrada's Endosomal Escape Vehicle-conjugated phosphorodiamidate morpholino oligomer is designed to enable the efficient intracellular delivery of a wide range of therapeutics, previously considered inaccessible and undruggable, into a variety of organs and tissues. Entrada's EEV-PMO uses an allele-specific approach that sterically blocks the triplet repeats in the mRNA that sequesters these critical proteins in order to restore muscle function. At the TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference, Entrada's clinical candidate ENTR-701 for DM1 was supported by new preclinical data indicating prolonged splicing correction in the tibialis anterior, triceps and quadriceps, and amelioration of myotonia in a DM1 mouse model following a single dose.

08:19 EDT McEwen Copper reports assay results from Los Azules project - McEwen Copper is pleased to report the latest assay results from its Los Azules project, which continues to deliver long intercepts of good grades. The drill program underway has three important objectives: Improve confidence in the resource by converting Inferred mineral resources to the Indicated category; Accelerate project advancement with metallurgical, hydrological and geotechnical drilling and Test the limits of the depth extension of the higher-grade mineralization. Results from this drilling program will be used to update the 2017 Los Azules PEA. The updated version will be released in Q1, 2023. Drilling has halted for the winter and will resume in October when spring arrives in Argentina. Earlier this year, Mining Intelligence ranked Los Azules as one of the world's top five largest undeveloped porphyry copper deposits that is not already owned by a major mining company. The opportunity to expand the deposit at depth remains open for further testing. While the median depth of drill holes within the Los Azules resource database is 175 meters (m), it is not uncommon for porphyry copper mineralization to extend well beyond a kilometer or more of depth. Numerous drill holes have encountered strong copper grades below the 2017 PEA pit bottom. Only three holes have been drilled to a depth of a kilometer and all encountered mineralization. The highest-grade mineral domains at Los Azules are clearly the hydrothermal and magmatic breccias and late-stage quartz veins which can extend kilometres to depth. There are numerous examples of such deposits in Argentina and Chile. The most recent is Filo Mining's spectacular assay results of earlier this year. The Filo deposit is 300 kilometres north of Los Azules, also in the San Juan province, Argentina. The deepest occurrence of a breccia at Los Azules is at a hole depth of some 810 m in drill hole AZ1299 and deepest occurrence of late-stage quartz veins is found at 990 m down the same hole. A dedicated exploration program associated with higher grade domains at Los Azules has not yet been conducted. Most holes drilled to date are vertical and intersect the breccias at very low angles. Improving our understanding of the nature and distribution of the highest-grade mineral zones at Los Azules is a priority for the upcoming drilling seasons.

08:17 EDT Xortx Therapeutics announces Pre-Phase 3 meeting date with FDA - XORTX Therapeutics is pleased to announce that the pre-Phase 3 meeting request made to the US Food and Drug Administration has resulted in the grant of a virtual meeting scheduled on September 16, 2022. In advance of this meeting, XORTX has submitted a "Pre-Phase-3 Briefing Package" to the FDA on Thursday, July 28, 2022. To date, the Company has successfully completed the research and development activities leading to this request and is advancing its XRx-008 program for the treatment of autosomal dominant polycystic kidney disease. R&D activities during the past year leading to this meeting request included manufacturing clinical quality GMP oxypurinol, finalizing formulation of drug product, and characterizing improved oral bio-availability of oxypurinol in animal models. The Company has achieved successful regulatory filings with the FDA and Health Canada and has commenced its OXY-XRX-101 bridging pharmacokinetics study. These important milestones have well positioned XORTX for this pre-Phase 3 meeting with the FDA. The Pre-Phase 3 Briefing Package provides an up-to-date summary of the extensive work completed for the XRx-008 program and this type B meeting. In addition, the briefing package presents an agenda including topics and questions for discussion related to the critical developmental steps necessary to complete the planned clinical registration trial and for the marketing approval application.

08:15 EDT U.S. Well Services announces 1-for-6 reverse stock split - U.S. Well Services announced it is executing a reverse stock split, effective August 4. Holders of the Company's Class A common stock will receive 1 post-split share for every 6 pre-split shares of Class A common stock. The reverse stock split will not modify any rights or preferences of the Company's stockholders, nor will it alter any stockholders' percentage interest in the Company. No fractional shares of Class A common stock will be issued as a result of the reverse stock split. Stockholders of record who would otherwise be entitled to receive a fractional share will receive one full share of post-split Class A common stock. The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The Company's Class A common stock will continue to be traded on the NASDAQ Capital Market under the symbol USWS and will begin trading on a split-adjusted basis when the market opens on Friday, August 5, 2022 under a new CUSIP number 91274U 309. The reverse stock split was approved by the Company's stockholders at its annual meeting held on May 20, 2022. Following the annual meeting, the Company's Board of Directors held a meeting and approved a reverse stock split ratio of 1-for-6.

08:12 EDT Magenta Therapeutics expects cash to fund operations into 2Q24 - Cash, cash equivalents and marketable securities as of June 30, 2022, were $139.4 million, compared to $176.9 million as of December 31, 2021. Magenta anticipates that its cash, cash equivalents and marketable securities will be sufficient to fund its current operational plan into Q2 2024.

08:11 EDT Replimune Group expects cash to fund operations into 2H of 2024 - As of June 30, 2022, cash, cash equivalents and short-term investments were $395.1 million, as compared to $395.7 million as of March 31, 2022. Cash utilized in operating activities in advancing the Company's expanded clinical development plan was offset by $31.0 million in net proceeds generated from the sale of common stock under the Company's at-the-market facility. Based on the current operating plan, Replimune believes that existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.

08:10 EDT C4 Therapeutics expects cash to fund operations to end of 2024 - Cash, cash equivalents and marketable securities as of June 30, 2022, were $397.8 million, compared to $451.5 million as of December 31, 2021. The decrease in cash was primarily driven by expenditures to fund operations. C4T expects that its cash, cash equivalents and marketable securities as of June 30, 2022, together with future payments expected to be received under existing collaboration agreements, will be sufficient to fund planned operating expenses and capital expenditures to the end of 2024.

08:04 EDT Focus Financial CFO 'very pleased' with strength of Q2 performance - "We are very pleased with the strength of our financial performance this past quarter. Although the markets were exceptionally volatile, our 2022 second quarter results were again above the top end of our guidance and the resilience of our revenue performance is notable. We have continued to deploy capital in an extremely disciplined, measured way, particularly given the heightened risks created by the broader macro environment. We are executing well and navigating this storm. As a result, we expect to be well-positioned to benefit from the growth opportunity once macro conditions improve and deliver incremental value to our shareholders," said Focus Financial Partners CFO Jim Shanahan.

08:02 EDT Atlas Air to be acquired by investor group for $5.2B - Atlas Air Worldwide (AAAW) announced that it has entered into a definitive agreement to be acquired by an investor group led by funds managed by affiliates of Apollo (APO) together with investment affiliates of J.F. Lehman & Company and Hill City Capital in an all-cash transaction with an enterprise valuation of approximately $5.2 billion. Under the terms of the agreement, Atlas Air Worldwide shareholders will receive $102.50 per share in cash, representing a 57% premium to the 30-day volume-weighted average trading price per share of Atlas Air Worldwide common stock as of July 29, 20221. Upon completion of the transaction, Atlas Air Worldwide will become a privately held company and shares of Atlas Air Worldwide common stock will no longer be listed on the Nasdaq stock exchange. Atlas Air Worldwide will continue operating under the Atlas Air Worldwide name, be led by John Dietrich and the current executive team and maintain its global presence. The transaction is expected to close in the fourth quarter 2022 or first quarter 2023, subject to customary closing conditions, including approval by Atlas Air Worldwide shareholders and receipt of regulatory approvals

08:00 EDT LGI Homes opens Tate Reserve near Alpharetta - LGI Homes announced Terrata Homes is now selling its newest community in the Atlanta, GA. market, The Tate Reserve. This stunning community offers homebuyers a variety of new, luxury homes with spacious layouts and high-end interior finishes, tucked along the foothills of the Appalachian Mountains. Featuring, acreage homesites, a 25-acre nature preserve with trails, a community clubhouse and access to Bent Tree Country Club, The Tate Reserve is where the beauty of nature and a modern lifestyle meet. Here you will find beautifully crafted, modern farmhouse style homes that are offset by the rolling hills and towering pine trees that define the neighborhood.

07:59 EDT Societal CDMO awarded CDMO service contracts by three new customers - Societal CDMO announced that it has been awarded CDMO service contracts from three new customers. The agreements span a range of the company's offerings including clinical trial services, analytical method and formulation development, and cGMP manufacturing, among others. Under terms of the first new contract, Societal will execute a range of clinical trial services to support the initiation of a U.S.-based Phase 2 clinical study of a novel melatonergic antidepressant already approved for use in Europe and Australia. Societal will be responsible for sourcing and preparing the study drug and matching placebo for use in the trial. Additional activities will include packaging and labeling of study drug and matching placebo, as well as storing the prepared materials and distributing them to clinical trial sites within the U.S. These activities will be conducted in collaboration at Societal's CDMO facilities in Georgia and California. The second agreement calls for Societal to conduct analytic method activities and development of a liquid oral formulation of an investigational treatment for pediatric patients with dietary restrictions suffering from neurological and neuropsychiatric diseases. Societal will also be responsible for the production and packaging of an initial engineering batch of the liquid oral formulation. The scope of work under the third new contract includes clinical trial services to support Phase 2 clinical studies of a novel antisense oligonucleotide being developed for the treatment of various cancers. Activities will include labeling and storage of vials of the investigational compound, as well as vial distribution to clinical trial sites.

07:57 EDT Xos makes initial deliver of battery-electric stepvans to Gabrielli Truck Sales - Xos announced it has signed a dealership agreement and initial delivery with Gabrielli Truck Sales to offer the suite of Xos vehicles to its customers across New York, New Jersey, and Connecticut. Gabrielli will be selling Xos' flagship Class 5 and 6 stepvan, along with its recently-unveiled medium-duty Class 6 and 7 chassis cab MDXT and heavy-duty Class 8 electric trailer HDXT, at 17 of its 19 locations across the Northeast.

07:54 EDT Gol Linhas announces preliminary July traffic figures - GOL Linhas Aereas Inteligentes S.A announces preliminary air traffic figures for the month of July, compared to the same period in 2021. Highlights: GOL's total supply (ASK) increased 42.6%. Total seats increased 41.9% and the number of departures increased by 44.7%. GOL's total demand (RPK) increased by 36.3% and the load factor was 80.8%. GOL's domestic supply (ASK) increased 31% and demand (RPK) increased by 24.1%. GOL's domestic load factor was 80.1%. The volume of departures increased by 40.2% and seats increased by 37.5%. GOL's international supply (ASK) was 309 million, the demand (RPK) was 275 million and international load factor was 88.9%.

07:48 EDT Alamos Gold names Luc Guimond as COO, succeeding Peter MacPhail - Alamos Gold announced the appointment of Luc Guimond as COO, effective September 1. As part of an established multi-year plan, Luc will succeed Peter MacPhail who will be retiring as of August 31. To support the transition, Peter will be staying with the company as a consultant until the third quarter of 2023. Luc Guimond has nearly 35 years of experience in the mining industry in operations management, project management, mine construction, and corporate development in Canada and Australia. He is currently Vice President of Operations at Alamos Gold. Prior to that, Luc was the General Manager of Young-Davidson where he oversaw its evolution from the development and construction stages, through to the successful completion of the lower mine expansion, resulting in record operating and financial performance in 2021.

07:46 EDT The Buckle reports July net sales up 4.2% to $97.7M - The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended July 30, 2022 increased 1.8 percent from comparable store net sales for the 4-week period ended July 31, 2021. Net sales for the 4-week fiscal month ended July 30, 2022 increased 4.2 percent to $97.7 million from net sales of $93.7 million for the prior year 4-week fiscal month ended July 31, 2021. Comparable store net sales for the 13-week second quarter ended July 30, 2022 increased 1.6 percent from comparable store net sales for the 13-week period ended July 31, 2021. Net sales for the 13-week fiscal second quarter ended July 30, 2022 increased 2.3 percent to $302.0 million compared to net sales of $295.1 million for the prior year 13-week fiscal second quarter ended July 31, 2021. Comparable store net sales year-to-date for the 26-week period ended July 30, 2022 increased 2.6 percent from comparable store net sales for the 26-week period ended July 31, 2021. Net sales for the 26-week fiscal period ended July 30, 2022 increased 2.8 percent to $611.0 million compared to net sales of $594.2 million for the prior year 26-week fiscal period ended July 31, 2021.

07:46 EDT Dyne Therapeutics expects cash to fund operations into H2 of 2024 - Cash position: Cash, cash equivalents and marketable securities were $291.8 million as of June 30, 2022, which is anticipated to fund operations into the second half of 2024.

07:42 EDT Royalty Pharma sees 2022 adjusted cash receipts $2.275B-$2.35B - Royalty Pharma now anticipates full-year 2022 Adjusted Cash Receipts to be between $2,275 million and $2,350 million, excluding transactions announced subsequent to the date of this release. This guidance reflects an estimated foreign exchange impact of ~-3% to -4% for FY 2022 year/year Adjusted Cash Receipts growth, assuming current exchange rates prevail for the balance of 2022.

07:37 EDT Dream Finders Homes reaffirms FY22 guidance of min 7,000 home closings - Dream Finders Homes is reaffirming its guidance of a minimum of 7,000 home closings for the full year 2022. This outlook considers the rapid increase in interest rates and overall moderation of the housing market that began at the end of the second quarter of 2022 and assumes general economic conditions, including interest rates and mortgage availability, remain similar to those experienced in the latter half of the second quarter of 2022. Additionally, any further COVID-19 governmental restrictions on land development, home construction or home sales or additional supply chain challenges could negatively impact the Company's ability to achieve this number of home closings in 2022. As of June 30, 2022, the Company backlog was 7,190 homes, with approximately 32% of the homes in backlog expected to be delivered in 2023 and beyond. The Company continues to believe the backlog of homes sold is the best indicator for future growth.

07:35 EDT Huntington Ingalls sees FY20-FY24 free cash flow $3.2B

07:34 EDT MDU Resources to separate Knife River via tax-free spinoff to shareholders - MDU Resources announced that its board of directors has unanimously approved a plan to separate its wholly owned construction materials business, Knife River Corporation, from the company. The separation will result in two independent, publicly traded and "well-capitalized" companies, which the MDU Resources board believes will "leave each positioned well for durable growth and shareholder value creation." The separation is expected to be effected as a tax-free spinoff to MDU Resources shareholders and to be completed in 2023. With the spinoff, it is expected that MDU Resources shareholders will retain their current shares of MDU Resources stock and receive a pro rata distribution of shares of Knife River stock in a transaction that is expected to be tax free to MDU Resources and its shareholders for U.S. federal income tax purposes. The actual number of shares to be distributed to MDU Resources shareholders will be determined prior to closing, as will the specific transaction structure. "We are taking an important step to significantly enhance the value inherent in our businesses by creating two focused, independent publicly traded companies. We are proud of the strong businesses we have built and are confident now is the right time to take this step to best serve our customers, employees, communities and shareholders. We expect this transaction to create significant value for our shareholders and believe it will enable us to achieve attractive shareholder returns at both companies," said David Goodin, president and CEO of MDU Resources.

07:31 EDT Arvinas expects cash to fund operating expenses beyond 2024 - Based on its current operating plane, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2022 is sufficient to fund planned operating expenses and capital expenditure requirements multiple years beyond 2024.

07:23 EDT Oncorus expects cash to fund operations into early 2024 - Oncorus expects its cash, cash equivalents and investments to fund its capital expenditures and operating expenses into early 2024.

07:22 EDT Gildan remains 'positive' in ability to delivery three-year objectives - The company said, "As we move into the second half of the year, while we have seen some slowing, we believe the recovery of large events and travel and tourism remains a tailwind to demand, which is supported by the feedback we are getting from our major imprintables distributors. Also, while we are seeing a softening retail environment, for Gildan this is primarily impacting national account customer sales of activewear, hosiery and underwear products, which represents a smaller part of our overall business. As such, given our record first half performance and the ongoing benefits of our Back to Basics strategy, combined with our shift to the GSG strategy, we remain positive as we move forward and confident about our ability to deliver on our three-year objectives announced earlier this year."

07:21 EDT Hecla Mining sees 2022 silver and gold production 12.9-13.5M oz. and 165-175K oz

07:19 EDT ProQR Therapeutics expects cash to fund operations into 2025 - On June 30, 2022, ProQR held cash and cash equivalents of EUR 156.4 million, compared to EUR 187.5 million on December 31, 2021. Net cash used in operating activities during the three-month period ended June 30, 2022 was EUR 14.8 million, compared to EUR 10.0 million for the same period last year.

07:15 EDT Bridger Aerospace to go public through combination with Jack Creek Investment

07:13 EDT Orchard Therapeutics expects cash to fund requirements into 2024 - Cash, cash equivalents and investments as of June 30, 2022, were $170.9 million, with $33.0 million of debt outstanding, compared to $220.1 million and the same debt figure as of December 31, 2021. During the first half of 2022, the company received approximately $18.5 million in cash from refundable tax credits related to qualifying expenditures in 2020 and 2019, which partially offset the cash used for operating activities during the first six months of 2022. The company expects that its existing cash, cash equivalents and investments will fund its anticipated operating, debt service and capital expenditure requirements into 2024.

07:10 EDT Johnson Controls on track to deliver FY productivity plan - Johnson Controls, in slides being presented on its Q3 earnings conference call, says it is on track to deliver on its productivity plan of ~$230M in savings for FY22, realizing ~$170M in cost savings YTD.

07:08 EDT Lee Enterprises reaffirms FY adjusted EBITDA view $95M-$98M

06:56 EDT Bio-Techne announces CEO transition plan - Bio-Teche announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's CEO effective June 30, 2024. The company's board of directors has begun its search for Kummeth's replacement, evaluating both internal and external candidates to assume the CEO position upon Kummeth's retirement at the end of its fiscal 2024. It is anticipated that Kummeth will continue to serve on Bio-Techne's board of directors upon his retirement.

06:52 EDT SeaWorld announces new $250M share repurchase program - The company also announced that its board of directors approved a new $250M share repurchase program. Under the share repurchase program, the company is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The share repurchase program has no time limit and may be suspended or discontinued completely at any time. The number of shares to be purchased and the timing of purchases will be based on the company's trading windows and available liquidity, general business and market conditions, and other factors, including legal requirements, share ownership thresholds, debt covenant restrictions and alternative investment opportunities.

06:44 EDT Duke Energy announces strategic review of the Commercial Renewables business

06:41 EDT Altice USA confirms inquiries for Suddenlink assets in earnings call - During its Q2 earnings call Q/A, CEO Dexter Goei stated: "I think we can confirm that we've received a lot of reverse inquiry for all or parts of the Suddenlink assets."

06:36 EDT CommScope reaffirms 2022 core adjusted EBITDA view $1.15B-$1.25B - "With the continued progress we are making through CommScope NEXT, we are re-affirming our commitment to full year 2022 Core adjusted EBITDA between $1.15 - $1.25 billion, as well as our year-end net leverage target of 6.8x - 7.2x," said Kyle Lorentzen, Chief Financial Officer. "As we drive our refocused investments in technology innovation, capacity expansion and operational efficiency throughout our portfolio, we believe CommScope is well positioned to deliver on our targets and create significant incremental shareholder value."

06:18 EDT Denbury raises share repurchase authorization by $100M to $350M

06:12 EDT Watts Water raises FY22 organic growth view to 8%-11% from 3%-8% - Raises FY22 adjusted operating margin view to 15.4%-15.9% from 14.5%-14.9%, and adjusted margin growth to up 110bps-160bps from up 20bps-60bps. Still sees FY free cash flow about 90% of net income.

06:08 EDT Plastiq to go public via merger with Colonnade Acquisition Corp. II - Plastiq Inc., the B2B payment platform powering the small and midsize business economy, and Colonnade Acquisition Corp. II, announced that they have entered into a definitive agreement and plan of merger. The combined company will continue as a publicly-listed entity and have an implied estimated enterprise value of approximately $480M at closing, based on current assumptions. Once closed, the combined company will operate under the name Plastiq and is expected to trade under a new ticker symbol. The Plastiq management team, led by Founder and CEO Eliot Buchanan, will continue to lead the company. The transactions contemplated by the agreement and plan of merger reflect an implied estimated enterprise value at closing of $480M, representing a 6.4x multiple to Plastiq's 2022 forecasted net revenue of $75M and a 4.6x multiple to Plastiq's 2023 forecasted net revenue of $105M. The Business Combination includes no secondary component and existing Plastiq equity holders will roll over their entire investments in Plastiq into the combined company. As a result of the Business Combination, Plastiq is expected to add approximately $320M to its balance sheet, offering significant capital flexibility for continued organic and inorganic growth. The Business Combination has been unanimously approved by the boards of both Plastiq and Colonnade. The Business Combination is expected to close in the first quarter of 2023, subject to the satisfaction of various closing conditions, including approval by the shareholders of Colonnade, the effectiveness of a registration statement to be filed with the SEC in connection with the Business Combination and other regulatory approvals.

05:41 EDT Meta to shut down Facebook Live Shopping feature on October 1 - Facebook is shutting down its live shopping feature on October 1 to shift its focus to Reels, the company announced in a blog post. The company said: "Beginning on October 1, 2022, you will no longer be able to host any new or scheduled Live Shopping events on Facebook. You will still be able to use Facebook Live to broadcast live events, but you won't be able to create product playlists or tag products in your Facebook Live videos. As consumers' viewing behaviors are shifting to short-form video, we are shifting our focus to Reels on Facebook and Instagram, Meta's short-form video product. If you want to reach and engage people through video, try experimenting with Reels and Reels ads on Facebook and Instagram. You can also tag products in Reels on Instagram to enable deeper discovery and consideration. If you have a shop with checkout and want to to host Live Shopping events on Instagram, you can set up Live Shopping on Instagram." Reference Link

05:22 EDT Sun Life Financial to sell UK business to Phoenix Group for GBP 248M - Sun Life Financial (SLF) announced it has entered into an agreement to sell Sun Life UK to Phoenix Group (PNXGF). Sun Life UK manages life and pension policies and annuity blocks for UK Clients. The company is closed to new sales and has been operating as a run-off business in the life and pension policies segment since 2001. Sun Life will sell Sun Life UK to Phoenix Group for a closing price of GBP 248M and will retain its economic interest in UK's payout annuities business. This transaction will also provide further growth opportunities for Sun Life's asset management businesses. As part of the sale, Sun Life will form a long-term partnership to become a strategic asset management partner to Phoenix Group. Sun Life's asset management companies, MFS and SLC Management, will continue to manage approximately C$9B of Sun Life UK's general account upon the close of the sale. Phoenix Group has set a goal to invest approximately $25B in North American public and private fixed income and alternative investments over the next five years. MFS and SLC Management will be material partners to Phoenix Group in achieving this goal. This transaction is expected to close during the first half of 2023, subject to receipt of regulatory approvals and satisfaction of customary closing conditions.

05:12 EDT UMC reports July sales of NT$24.83M, up 35.18%

05:07 EDT Kaixin Auto obtains $700M to invest in pending acquisition of EV manufacturer - Kaixin Auto announced that it has obtained a total of $700M of targeted investment intentions from several institutional investors. The investments will take effect simultaneously with Kaixin's intended acquisition of a new energy vehicle manufacturing company. The investors intend to subscribe for the company's convertible preferred shares with a conversion price of at least $2.00 per share, which are to be issued concurrent with the intended acquisition transaction. Since the establishment of its new energy vehicle business department in August 2021, Kaixin has been actively seeking new energy vehicle manufacturers as acquisition targets. The company has already identified a preliminary acquisition target and been in active negotiations with a number of investment funds. The above mentioned $700M investments would be allocated to new energy vehicle business operations at completion of the intended acquisition of the new energy vehicle manufacturing company. Mingjun Lin, chairman and CEO of Kaixin, said: "A large amount of capital would be necessary to support business operations of the acquired EV manufacturer. The securing of the $700 million investment intentions helps strengthen our position to accelerate the acquisition process. We expect to announce the target company in August."